A5035856152- Cutaneous lymphoproliferative disorders research
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Autoimmune Bullous Skin Diseases
- Cell Adhesion Molecules Research
- Cutaneous Melanoma Detection and Management
- Fungal Infections and Studies
- Melanoma and MAPK Pathways
- T-cell and Retrovirus Studies
- Eosinophilic Disorders and Syndromes
- Virus-based gene therapy research
- Cancer Immunotherapy and Biomarkers
- Nonmelanoma Skin Cancer Studies
- Cancer and Skin Lesions
- Inflammatory Myopathies and Dermatomyositis
- melanin and skin pigmentation
- RNA regulation and disease
- Skin and Cellular Biology Research
- Vascular Tumors and Angiosarcomas
- Wound Healing and Treatments
- Cancer Cells and Metastasis
- Nail Diseases and Treatments
- Immune Cell Function and Interaction
- Skin Diseases and Diabetes
Osaka University
2015-2024
Saint John's Health Center
2013-2024
Molecular Oncology (United States)
2013-2024
Osaka University Hospital
2019-2021
Gene Therapy Laboratory
2011
Melanoma brain metastasis (MBM) represents a frequent complication of cutaneous melanoma. Despite aggressive multi-modality therapy, patients with MBM often have survival rate <1 year. Alteration in DNA methylation is major hallmark tumor progression and metastasis; however, it remains largely unexplored MBM. In this study, we generated comprehensive landscape through the use genome-wide copy number, gene expression data integrative analysis melanoma to A progressive demethylation low CpG...
E7777 is a recombinant cytotoxic fusion protein composed of the diphtheria toxin fragments A and B human interleukin-2. It shares an amino acid sequence with denileukin diftitox, but has improved purity increased percentage active monomer. We undertook multicenter, single-arm phase II study in patients relapsed or refractory peripheral T-cell lymphoma (PTCL) cutaneous (CTCL) to evaluate its efficacy, safety, pharmacokinetics, immunogenicity. total 37 were enrolled, which 17 19 had PTCL CTCL,...
Summary Melanoma brain metastasis ( MBM ) is frequent and has a very poor prognosis with no current predictive factors or therapeutic molecular targets. Our study unravels the alterations of cell‐surface glycoprotein CD 44 variants during melanoma progression to . High expression splicing variant 6 44v6) in primary PRM regional lymph node metastases from AJCC Stage IIIC patients significantly predicts development. The 44v6 also enhances migration cells by hyaluronic acid hepatocyte growth...
Abstract BACKGROUND Circulating tumor cells (CTC) have been found in patients with metastatic melanoma and are associated advanced stage poor patient outcome. We hypothesize that CTC harbor genomic changes critical the development of distant systemic metastasis. Here, we present first genome-wide copy-number aberration (CNA) loss heterozygosity (LOH)-based characterization CTC. METHODS were isolated from peripheral blood monocytes 13 regional metastasis IIIB/C using antibodies against...
Melanoma metastasis to the brain is one of most frequent extracranial tumors. Cell surface gangliosides are elevated in melanoma metastasis; however, metabolic regulatory mechanisms that govern these specific changes poorly understood particularly metastases (MBM) development. We found ganglioside GD3 levels significantly upregulated MBM compared lymph node (LNM) but not for other gangliosides. Moreover, we demonstrated an upregulation ST8SIA1 (GD3 synthase) as progresses from melanocytes...
Annular erythema has been recognized to be a specific, cutaneous manifestation associated with Sjögren's syndrome. Based on search of the literature up 2007, annular syndrome (AESS) preferentially occurs in Asian but not Western populations. However, precise clinical course and standard regimen for management AESS have remained obscure, primarily because its rare occurrence populations fact that most cases are isolated reports. In this study, 28 from our department 92 distilled were enrolled...
Central hypothyroidism and dyslipidemia are well-known adverse events (AEs) of bexarotene therapy. Although is known to cause dyslipidemia, no study has examined the association between in patients undergoing The aim this examine association. A retrospective observational was performed among 294 who initiated therapy Japan (nation-wide postmarketing complete surveillance). Jonckheere-Terpstra (one sided) test evaluate effect dose on lipid metabolisms, regression analyses were associations...
Brentuximab vedotin (BV), a conjugate of anti-CD30 antibody and monomethyl auristatin E, has emerged as promising treatment option for refractory CD30+ mycosis fungoides (MF) primary cutaneous anaplastic large-cell lymphoma (pcALCL). BV been shown to be safe effective in treating Hodgkin's peripheral T-cell lymphoma. This multicenter, prospective, single-arm phase I/II study evaluated the efficacy Japanese patients with lymphomas, namely Participants were divided into two groups: those MF or...
Ontuxizumab (MORAb-004) is a humanized recombinant antibody targeting endosialin (TEM-1, CD248). We conducted an analysis of expression in metastatic melanoma specimens using the anti-endosialin rat anti- MAb 9G5, order to determine potential as therapeutic target within tumor microenvironment vasculature. Endosialin paraffin-embedded archival tissue block (PEAT) tissues was assessed immunohistochemistry (IHC) with anti-endosialin, vessels American Joint Commission on Cancer (AJCC) Stage III...
Abstract Mucosal melanoma of the nasal cavity is a rare disease that has been consistently associated with poor outcome. While complete surgical excision offers only prospect cure, it high risk morbidity due to challenging anatomical location, and most patients still develop incurable metastatic disease. The efficacy immunotherapy on mucosal lower in comparison cutaneous melanoma, rarely BRAF mutations. Although preclinical data have shown combination treatment immune checkpoint inhibitors...
The present study (B-1201 clinical trial) was conducted as a multicenter, open-label, single-arm phase II to evaluate the long-term safety, tolerability and efficacy of bexarotene. This enrolled 10 Japanese adults aged more than 20 years with cutaneous T-cell lymphoma (CTCL) who completed 24-week period B-1101 trial. objective response rate (ORR) 53.8% (95% confidence interval, 25.1-80.8). In early stage (IB), ORR 60% (3/5 cases). advanced (IIB IIIA), 57.1% (4/7 median time 58 days (range,...
Abstract SR-0379 is a functional peptide that has wound healing effect with anti-microbial action, making it an ideal drug to prevent infection. To evaluate the safety, efficacy, and pharmacokinetics of for treatment leg ulcers, physician-initiated, phase I/IIa, first-in-patient clinical study was designed. A multi-center, double-blind, randomized conducted from October 2015 September 2016. The inclusion criteria ulcers were (1) diabetes or critical limb ischemia (2) size <6 cm in...